Fiona Legere, Toronto

About Fiona

Fiona is a dynamic litigator who provides strategic advice on intellectual property (IP) matters to businesses in the life sciences, telecommunications and technology industries. She advises on IP strategy, patent and Patented Medicines (Notice of Compliance) proceedings, and regulatory, trademark and copyright issues. Fiona has a significant trial and appellate litigation practice, focusing almost exclusively on complex commercial intellectual-property litigation.

Known for her highly personable and pragmatic approach, Fiona is a trusted advisor to many pharmaceutical and technology companies. She has managed and coordinated multi-jurisdictional patent enforcement actions and successfully acted as counsel in groundbreaking patent cases, including the first biologics case and non-practising entity (NPE) case in Canada.

Fiona has an impressive track record of successfully representing many clients in court proceedings, including before the Ontario Superior Court, the Ontario Court of Appeal, the Federal Court of Canada and the Federal Court of Appeal.

Fiona also has clients who rely on her to negotiate complex strategic settlements and business agreements with a keen eye for ensuring positive outcomes.

Select Experience

Some of Fiona’s recent notable matters include representing:

EMD Serono and Merck Serono in ongoing patent litigation involving the drug Mavenclad (cladribine)
Regeneron and Bayer in several ongoing patent infringement actions involving the blockbuster drug Eylea (aflibercept)
AbbVie in several ongoing patent infringement actions involving the blockbuster drug Humira (adalimumab), in which AbbVie was successful in finding that the formulation patent was valid and infringed (AbbVie Corporation v. Jamp Pharma Corporation)
Merck in a patent impeachment trial against Pfizer related to a pneumococcal conjugate vaccine (V114), in which Merck successfully cleared the path to launch its V114 vaccine in Canada (Merck v. Wyeth)
Bell Canada and Telus in a patent infringement trial involving their internet protocol television systems against Rovi, in which the court dismissed Rovi’s case and found all four asserted patents invalid (Rovi Guides et al. v. Bell Canada and Telus)
Bell Canada in a trademark infringement lawsuit involving Bell’s Fibe trademark
Bell Canada, Telus and Rogers in a patent infringement action commenced by TracBeam involving wireless telecommunication services
Bell Canada in a patent infringement trial relating to Fibe TV against Mediatube, in which the court dismissed Mediatube’s case and found that the patent was not infringed (Mediatube v. Bell Canada)

Awards & Recognition

Fiona is continuously recognized as a leading intellectual property lawyer in the following publications and awards, including in the most recent editions:

The Legal 500 Canada – 2024–2025 (Intellectual Property)
Chambers Canada: Canada's Leading Lawyers for Business 2025 (Intellectual Property: Litigation)
Chambers Canada: Canada’s Leading Lawyers for Business 2024 (Up and Coming – Intellectual Property: Litigation)
The Canadian Legal Lexpert Directory 2023 (Litigation: Intellectual Property)
Benchmark Canada: The Definitive Guide to Canada's Leading Litigation Firms and Attorneys 2024 (Litigation Star – Intellectual Property; 40 & Under List)
Lexpert Special Edition: Technology and Health Sciences 2024
Managing Intellectual Property’s IP Stars 2024 (Patent Star)
IAM Patent 1000: The World's Leading Patent Professionals 2024 (Silver – Litigation)
Who’s Who Legal: Life Sciences 2024 (Patent Litigation)
Who’s Who Legal: Canada 2023 (Life Sciences and Patents)
Who’s Who Legal: Intellectual Property 2023 (Patents)
Lexpert Rising Stars 2023: Leading Lawyers Under 40
Managing IP Americas Awards 2015 (Team member – Patent Contentious Team of the Year, Canada, and Milestone Case of the Year, Canada – represented Abbvie Corporation and others in Canada’s first patent infringement trial relating to biologics)